Cover Image

Hematological Events Potentially Associated with CDK4/6 Inhibitors: An Analysis from the European Spontaneous Adverse Event Reporting System

Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are a recent targeted therapy approved for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2−) advanced breast cancer. Abemaciclib, palbociclib and ribociclib demonstrated great efficacy and saf...

Full description

Saved in:

Bibliographic Details
Main Authors:	Vera Martins (Author), Mafalda Jesus (Author), Luísa Pereira (Author), Cristina Monteiro (Author), Ana Paula Duarte (Author), Manuel Morgado (Author)
Format:	Book
Published:	MDPI AG, 2023-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system
by: Jun Shen, et al.
Published: (2024)

Infection associated with CDK4/6 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database
by: Jinhua Chen, et al.
Published: (2024)

Cardiac Events Potentially Associated to Remdesivir: An Analysis from the European Spontaneous Adverse Event Reporting System
by: Concetta Rafaniello, et al.
Published: (2021)

META-INSTI: metabolic adverse events following integrase strand transfer inhibitor administration in spontaneous adverse event reports
by: Milena M Murray, et al.
Published: (2023)

The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials
by: Dongqing Pu, et al.
Published: (2024)

Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS
by: Xiaojiang Tian, et al.
Published: (2022)

Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems
by: Han N, et al.
Published: (2021)

Commentary: Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS
by: Jeanne M. Schilder, et al.
Published: (2023)

Comparison of Adverse Event Profiles of Tumor Necrosis Factor-Alfa Inhibitors: Analysis of a Spontaneous Reporting Database
by: Wakabayashi T, et al.
Published: (2020)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Lingqing Ding, et al.
Published: (2022)

Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)
by: Yiwen Bao, et al.
Published: (2024)

Analysis of Adverse Events of Cholinesterase Inhibitors and NMDA Receptor Antagonists on Arrhythmias Using the Japanese Adverse Drug Event Report Database
by: Shotaro Kobayashi, et al.
Published: (2023)

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
by: Jing Huang, et al.
Published: (2020)

Potential Adverse Events Reported With the Janus Kinase Inhibitors Approved for the Treatment of Rheumatoid Arthritis Using Spontaneous Reports and Online Patient Reviews
by: Yun-Kyoung Song, et al.
Published: (2022)

Vemurafenib-Induced Toxic Epidermal Necrolysis: An Emerging Adverse Event
by: Ana Filipe Monteiro, et al.
Published: (2018)

Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
by: Zoe Apalla, et al.
Published: (2021)

Gender differences in spontaneous adverse event reports associated with zolpidem in South Korea, 2015-2019
by: Kyung-In Joung
Published: (2023)

Hospital deaths and adverse events in Brazil
by: Pavão Ana Luiza B, et al.
Published: (2011)

Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
by: Ming-Tao Wen, et al.
Published: (2024)

NURSES' KNOWLEDGE ABOUT ADVERSE EVENTS AND THE CHALLENGES OF REPORTING THESE EVENTS
by: Jamilly Santos Araujo, et al.
Published: (2016)

Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
by: Zhen Li, et al.
Published: (2020)

CDK4/6 inhibitors in advanced breast cancer, what is beyond?
by: Amrallah A. Mohammed, et al.
Published: (2019)

Temporal changes in cyclinD-CDK4/CDK6 and cyclinE-CDK2 pathways: implications for the mechanism of deficient decidualization in an immune-based mouse model of unexplained recurrent spontaneous abortion
by: Zhuo Chang, et al.
Published: (2022)

The Reporting Frequency of Ketoacidosis Events with Dapagliflozin from the European Spontaneous Reporting System: The DAPA-KETO Study
by: Gabriella di Mauro, et al.
Published: (2022)

Adverse Events Following Immunization
by: L.I. Chernyshova
Published: (2014)

Evaluating adverse events in databases
by: Katie Lovell, et al.
Published: (2023)

Adverse Events of DOACs in Children
by: Alessandra Bosch, et al.
Published: (2022)

Cutaneous Adverse Events of Targeted Therapies and Immune-Checkpoint Inhibitors in Patients with Melanoma
by: Rita Pimenta, et al.
Published: (2021)

Signal mining of adverse events of proteasome inhibitors in multiple myeloma based on FAERS
by: Yuan Peng, et al.
Published: (2024)

Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A Practical Review
by: François Zammit, et al.
Published: (2024)

Methotrexate-related adverse events and impact of concomitant treatment with folic acid and tumor necrosis factor-alpha inhibitors: An assessment using the FDA adverse event reporting system
by: Kenji Onda, et al.
Published: (2023)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
by: Xiaoyin Bai, et al.
Published: (2021)

Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases
by: Nomura K, et al.
Published: (2015)

Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
by: K. Chanprapaph, et al.
Published: (2014)

Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review
by: Ling Gao, et al.
Published: (2019)

Immune-related adverse events in small-cell lung cancer patients treated with immune checkpoint inhibitors: a comprehensive analysis from the FDA adverse event reporting system
by: Yifeng Bai, et al.
Published: (2024)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2022)

Vonoprazan-associated infection: an analysis of the Japanese Adverse Drug Event Report and the FDA Adverse Event Reporting System
by: Mengling Ouyang, et al.
Published: (2024)

Adverse events related to neuromuscular blocking agents: a disproportionality analysis of the FDA adverse event reporting system
by: Liangxia Li, et al.
Published: (2024)

Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system
by: Xianglin Pan, et al.
Published: (2024)